SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

$SOPH
$XYL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Fluid Controls
Industrials
Get the next $SOPH alert in real time by email

Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting

BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023.

An award-winning powerhouse in the global technology space, Tretikov is currently Deputy Chief Technology Officer at Microsoft, where she previously served as Corporate Vice President in AI. Before joining Microsoft, Tretikov was CEO and Vice Chair of Terrawatt for two years and served as CEO of Wikipedia and Wikimedia.

"Lila is a tremendous leader in the artificial intelligence (AI) and technology worlds, with robust experience in bringing companies to scale on a global level. As the founder of several technology companies throughout her career, her entrepreneurial spirit combined with her executive leadership skills and comprehensive experience in AI will complement and add depth to our board and help take SOPHiA GENETICS to the next level," said Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS.

Once appointed to the SOPHiA GENETICS Board of Directors, Tretikov will succeed Milton Silva-Craig and join its current members Jurgi Camblong, Troy Cox, Kathy Hibbs, Didier Hirsch, Vincent Ossipow, Tomer Berkovitz and Jean-Michel Cosséry in developing the company's sustainable growth and strategy.

"Throughout my career, I've focused on finding projects that create outsized socio-economic impact by leveraging cutting-edge technology. Artificial intelligence has the potential to create positive change for humanity, and especially in medicine and biology," said Lila Tretikov. "SOPHiA GENETICS is revolutionizing the healthcare industry and I am looking forward to working with them to help further their mission of democratizing data-driven medicine."

Tretikov currently serves as a board director for Onfido (a privately-held digital identity tech company). She is also a member of the board of directors of Volvo Cars (NASDAQ:VOLCAR) and Xylem (NYSE:XYL).

She graduated from the University of California, Berkeley with a degree in Computer Science, Art and Artificial Intelligence, and has completed executive graduate programs at Stanford University and the University of Oxford.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram

About SOPHiA GENETICS 

SOPHiA GENETICS (NASDAQ:SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-nomination-of-lila-tretikov-to-board-of-directors-301837860.html

SOURCE SOPHiA GENETICS

Get the next $SOPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SOPH
$XYL

CompanyDatePrice TargetRatingAnalyst
12/18/2024$11.00Buy
Craig Hallum
12/12/2024Outperform → Peer Perform
Wolfe Research
12/9/2024$135.00 → $148.00Neutral → Buy
Citigroup
9/3/2024$138.00Buy → Hold
TD Cowen
8/13/2024$165.00Buy
UBS
8/7/2024$10.00 → $5.00Overweight → Equal-Weight
Morgan Stanley
6/27/2024$6.00Buy
Guggenheim
3/12/2024$150.00Outperform
Exane BNP Paribas
More analyst ratings

$SOPH
$XYL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Xylem to Release First Quarter 2025 Financial Results on April 29, 2025

    Xylem Inc. (NYSE:XYL), a leading global water solutions company that empowers customers and communities to build a more water-secure world, will release its first quarter 2025 results at 6:55 a.m. (ET) on April 29, 2025. At 9:00 a.m. (ET), Xylem's senior management team will host a conference call with investors. The call can be accessed by calling +1 (866) 777-2509 (US) or +1 (412) 317-5413 (INTL) or by visiting Investors Events | Xylem US. A replay of the briefing will be available on Investors Events | Xylem US and via telephone from April 29, 2025, 1:00 p.m. (ET) until May 13, 2025, at 11:59 p.m. (ET). The telephone replay will be available at +1 (877) 344-7529 or +1 (412) 317-0088 (I

    $XYL
    Fluid Controls
    Industrials
  • Hayward Appoints Water Industry Powerhouse Ron Keating to Board of Directors

    Hayward Holdings, Inc. (NYSE:HAYW) Board of Directors appointed Ron Keating to serve as its newest independent director, effective immediately. The Hayward Board now comprises 10 directors, nine of whom are independent. "The appointment of Ron Keating to our Board lends direct global operational and financial expertise to Hayward, along with critical expertise in the water industry," said Kevin Holleran, Hayward President, CEO and Director. "Ron's distinguished career and reputation as a decisive leader brings strategic and practical judgement as we continue to execute our growth strategies and deliver value to shareholders." Keating currently serves as president, chief executive officer

    $HAYW
    $XYL
    Industrial Machinery/Components
    Industrials
    Fluid Controls
  • SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC

    BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data. "When we announced one million profiles analyzed in 2022, it was a la

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SOPH
$XYL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SOPH
$XYL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SOPH
$XYL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SOPH
$XYL
SEC Filings

See more

$SOPH
$XYL
Leadership Updates

Live Leadership Updates

See more
  • Hayward Appoints Water Industry Powerhouse Ron Keating to Board of Directors

    Hayward Holdings, Inc. (NYSE:HAYW) Board of Directors appointed Ron Keating to serve as its newest independent director, effective immediately. The Hayward Board now comprises 10 directors, nine of whom are independent. "The appointment of Ron Keating to our Board lends direct global operational and financial expertise to Hayward, along with critical expertise in the water industry," said Kevin Holleran, Hayward President, CEO and Director. "Ron's distinguished career and reputation as a decisive leader brings strategic and practical judgement as we continue to execute our growth strategies and deliver value to shareholders." Keating currently serves as president, chief executive officer

    $HAYW
    $XYL
    Industrial Machinery/Components
    Industrials
    Fluid Controls
  • Matthew Pine, President and Chief Executive Officer of Xylem, Joins Trane Technologies Board of Directors

    Trane Technologies (NYSE:TT), a global climate innovator, announced the appointment of Matthew Pine, president and CEO, Xylem Inc. (NYSE:XYL), to its Board of Directors, effective April 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131141202/en/Matthew Pine, President and Chief Executive Officer of Xylem, Joins Trane Technologies Board of Directors (Photo: Business Wire) "Matthew will be a strong addition to our Board of Directors given his global leadership experience and proven track record of transformation in large industrial companies," said Dave Regnery, chair and CEO of Trane Technologies. "His passion for su

    $TT
    $XYL
    Auto Parts:O.E.M.
    Industrials
    Fluid Controls
  • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

    BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SOPH
$XYL
Financials

Live finance-specific insights

See more
  • Xylem to Release First Quarter 2025 Financial Results on April 29, 2025

    Xylem Inc. (NYSE:XYL), a leading global water solutions company that empowers customers and communities to build a more water-secure world, will release its first quarter 2025 results at 6:55 a.m. (ET) on April 29, 2025. At 9:00 a.m. (ET), Xylem's senior management team will host a conference call with investors. The call can be accessed by calling +1 (866) 777-2509 (US) or +1 (412) 317-5413 (INTL) or by visiting Investors Events | Xylem US. A replay of the briefing will be available on Investors Events | Xylem US and via telephone from April 29, 2025, 1:00 p.m. (ET) until May 13, 2025, at 11:59 p.m. (ET). The telephone replay will be available at +1 (877) 344-7529 or +1 (412) 317-0088 (I

    $XYL
    Fluid Controls
    Industrials
  • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

    BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025

    BOSTON and ROLLE, Switzerland, Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally,

    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SOPH
$XYL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more